Evidence map›Paper›PMID 30633508›Full record

ArticleBioconjugate chemistry2019

Targeting Fluorescent Nanodiamonds to Vascular Endothelial Growth Factor Receptors in Tumor.

Marco D Torelli, Ashlyn G Rickard, Marina V Backer, Daria S Filonov, Nicholas A Nunn, Alexander V Kinev, Joseph M Backer, Gregory M Palmer, Olga A Shenderova

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Targeting Nanodiamonds to the Nucleus in Yeast Cells.Nanomaterials (Basel, Switzerland) · 2020
    Article
  11. Article
  12. A Perspective on Fluorescent Nanodiamond Bioimaging.Small (Weinheim an der Bergstrasse, Germany) · 2019
    Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Marco D TorelliAdámas Nanotechnologies, Inc. , Raleigh , North Carolina 27617 , United States.
Ashlyn G RickardDepartment of Radiation Oncology , Duke University , Durham , North Carolina 27710 United States.
Marina V BackerSibTech, Inc. , Brookfield , Connecticut 06804 , United States.
Daria S FilonovCreative Scientist, Inc. , Research Triangle Park , North Carolina 27509 , United States.
Nicholas A NunnAdámas Nanotechnologies, Inc. , Raleigh , North Carolina 27617 , United States.
Alexander V KinevCreative Scientist, Inc. , Research Triangle Park , North Carolina 27509 , United States.
Joseph M BackerSibTech, Inc. , Brookfield , Connecticut 06804 , United States.
Gregory M PalmerDepartment of Radiation Oncology , Duke University , Durham , North Carolina 27710 United States.
Olga A ShenderovaAdámas Nanotechnologies, Inc. , Raleigh , North Carolina 27617 , United States.
Adámas Nano (United States) · USCreative Scientist (United States) · USDuke University · USSibtech (United States) · US

Funding

UNC Neuroscience Center Research Cores: MicroscopyP30NS045892 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ZYLKA, MARK J. · 2003 to 2022
$11.5M
Preclinical CoreU54HD079124 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BELGER, AYSENIL · 2013 to 2019
$8.0M
NHLBI NIH HHS HHSN268201500010CNICHD NIH HHS U54 HD079124NINDS NIH HHS P30 NS045892
6 · The paper itself

Abstract

The increased expression of vascular endothelial growth factor (VEGF) and its receptors is associated with angiogenesis in a growing tumor, presenting potential targets for tumor-selective imaging by way of targeted tracers. Though fluorescent tracers are used for targeted in vivo imaging, the lack of photostability and biocompatibility of many current fluorophores hinder their use in several applications involving long-term, continuous imaging. To address these problems, fluorescent nanodiamonds (FNDs), which exhibit infinite photostability and excellent biocompatibility, were explored as fluorophores in tracers for targeting VEGF receptors in growing tumors. To explore FND utility for imaging tumor VEGF receptors, we used click-chemistry to conjugate multiple copies of an engineered single-chain version of VEGF site-specifically derivatized with trans-cyclooctene (scVEGF-TCO) to 140 nm FND. The resulting targeting conjugates, FND-scVEGF, were then tested for functional activity of the scVEGF moieties through biochemical and tissue culture experiments and for selective tumor uptake in Balb/c mice with induced 4T1 carcinoma. We found that FND-scVEGF conjugates retain high affinity to VEGF receptors in cell culture experiments and observed preferential accumulation of FND-scVEGF in tumors relative to untargeted FND. Microspectroscopy provided unambiguous determination of FND within tissue by way of the unique spectral shape of nitrogen-vacancy induced fluorescence. These results validate and invite the use of targeted FND for diagnostic imaging and encourage further optimization of FND for fluorescence brightness.

Indexed as

AnimalsClick ChemistryFemaleFluorescent DyesHEK293 CellsHumansMice, Inbred BALB CMice, NudeModels, MolecularNanodiamondsNeoplasmsOptical ImagingReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor AFluorescent DyesNanodiamondsReceptors, Vascular Endothelial Growth FactorVascular Endothelial Growth Factor A

Identifiers

PMID30633508
PMCPMC7605622
OpenAlexW2910461564

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.